

May 13, 2009



SCYNEXIS and Medicines for Malaria Venture Sign HEOS(R) Agreement

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- SCYNEXIS, Inc. and Medicines for Malaria Venture (MMV) announced today that they have signed an agreement giving MMV access to SCYNEXIS' proprietary HEOS(R) drug discovery software platform for use in the organization's anti-malarial research projects.

The HEOS^(R) software suite is a comprehensive, web-based drug research information management software that supports geographically distributed scientists and facilitates collaboration.

"SCYNEXIS is proud that MMV has chosen HEOS software technology for its use in its important global anti-malarial project activities," said SCYNEXIS President & CEO Yves Ribeill. "HEOS(R) has been used for a number of years with our big pharma customers and we are pleased that world-class technologies such as HEOS can now be directed toward the fight against malaria and other neglected diseases."

"The HEOS database developed by SCYNEXIS will facilitate the sharing of data and other information concerning our drug development projects," said Tim Wells, MMV's Chief Scientific Officer. "Our scientific team is excited about using a facility that can be a secure repository of MMV scientific data. MMV is committed to the discovery of new compounds and molecules active against the malaria parasite that can eventually be developed into antimalarial medicines. Once the HEOS database is fully populated with MMV data, it is expected to facilitate our research and help us accelerate the development of new medicines for malaria."

The agreement allows MMV researchers worldwide to be networked through the HEOS(R) collaboration platform.

About SCYNEXIS

SCYNEXIS is a premier drug discovery and development company delivering effective and innovative drug pipeline solutions to pharmaceutical and global health partners. The Company, which is located in Research Triangle Park, North Carolina, is also focused on developing a proprietary internal pipeline based on cyclophilin inhibitors, a class of drugs that hold significant potential for the treatment of a broad range of diseases. Please visit our website at www.scynexis.com.

About Medicines for Malaria Venture

Medicines for Malaria Venture (MMV) is a not-for-profit organization created to discover, develop and deliver effective and affordable antimalarial drugs through public-private partnerships. MMV's vision is a world in which these innovative medicines will cure and

protect the millions at risk of malaria and help to ultimately eradicate this terrible disease.

MMV is currently managing the largest-ever portfolio of antimalarial projects in collaboration with over 100 pharmaceutical, academic, and endemic-country partners in 38 countries. The portfolio includes 19 completely new classes of compounds. New and improved treatment solutions are urgently needed for the 2.4 billion people at risk from malaria. MMV is working to ensure that its products will have the greatest possible public health impact and, most importantly, save lives. For more information, please consult <http://www.mmv.org>.

About HEOS^(R)

The HEOS^(R) software suite is a comprehensive, web-based drug research information management software that supports geographically distributed scientists and facilitate collaboration.

The complex process of transforming a hit into a clinical candidate involves data generated by a broad range of sources. The success of the project relies on the capability of the partners to easily, securely and efficiently access, share and communicate the right information at the right time. HEOS^(R) is a web portal that provides a secure and user-friendly data handling system. It allows all the involved collaborators to view results and make informed decisions.

HEOS^(R) is powered by Accelrys tools including Accord data cartridge and Pipeline Pilot which are provided under special arrangement by Accelrys for use in neglected disease research.

Source: SCYNEXIS, Inc.